Prepaid clinical trial and preclinical study costs
14,960
4,021
8,053
21,891
Prepaid expenses and other current assets
941
1,224
1,806
2,242
Total current assets
517,564
608,209
715,598
738,703
Right-of-use assets
4,010
0
85
666
Deferred financing costs
-
-
0
0
Restricted cash
211
-
-
-
Deposits
113
33
46
46
Total assets
521,898
608,242
715,729
739,415
Accounts payable
69,012
67,183
53,251
4,413
Other accrued liabilities
40,483
39,142
23,279
21,217
Lease liability, current
161
0
137
437
Total current liabilities
109,656
106,325
76,667
26,067
Lease liability, net of current portion
3,925
-
0
318
Total long-term liabilities
3,925
-
0
318
Total liabilities
113,581
106,325
76,667
26,385
Common stock, 0.00001 par value 300,000,000 shares authorized at june 30, 2026 and december 31, 2025 116,652,937 shares issued and outstanding at june 30, 2026 and 114,793,067 shares issued and outstanding at december 31, 2025
1
1
1
1
Treasury stock at cost, no shares at december 31, 2025 and december 31, 2024
-
-
0
0
Additional paid-in capital
1,543,362
1,508,643
1,486,229
1,402,539
Accumulated deficit
-1,133,893
-1,005,871
-847,546
-689,884
Accumulated other comprehensive (loss) gain
-1,153
-856
378
374
Total stockholders equity
408,317
501,917
639,062
713,030
Total liabilities and stockholders equity
521,898
608,242
715,729
739,415
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.